| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
Division of Endocrinology, Department of Medicine, University of Essen, Essen, Germany.
OBJECTIVE: To investigate the prevalence of autoimmune thyroiditis (AIT) in patients with polycystic ovary syndrome (PCOS). DESIGN: Over a period of 30 months, 175 patients with PCOS were recruited to a prospective multicenter study to evaluate thyroid function and morphology; 168 age-matched women without PCOS were studied as a control group. METHODS: PCOS was defined as a- or oligomenorrhea, hyperandrogenism and exclusion of other disturbances of estrogen or androgen synthesis. All laboratory parameters were determined with automated immunoassays. Thyroid morphology was assessed by ultrasound. RESULTS: PCOS patients were characterized by an increased LH/FSH ratio, low progesterone, elevated testosterone and a high prevalence of hirsutism (PCOS 83%, control 3%; mean hirsutism score 12+/-5 and 3+/-2 respectively), but no differences in estrogen levels were found. Thyroid function and thyroid-specific antibody tests revealed elevated thyroperoxidase (TPO) or thyroglobulin (TG) antibodies in 14 of 168 controls (8.3%), and in 47 of 175 patients with PCOS (26.9%; P<0.001). On thyroid ultrasound, 42.3% of PCOS patients, but only 6.5% of the controls (P<0.001) had a hypoechoic tissue typical of AIT; while thyroid hormone levels were normal in all subjects, PCOS patients had a higher mean TSH level (P<0.001) and a higher incidence of TSH levels above the upper limit of normal (PCOS 10.9%, controls 1.8%; P<0.001). CONCLUSION: This prospective study demonstrates a threefold higher prevalence of AIT in patients with PCOS, correlated in part with an increased estrogen-to-progesterone ratio and characterized by early manifestation of the disease.
This article has been cited by other articles:
|
|
 |
|
  R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H. F. Escobar-Morreale, W. Futterweit, O. E. Janssen, R. S. Legro, R. J. Norman, A. E. Taylor, et al. Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4237 - 4245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kourtis, D. Rousso, C. Balaris, D. Farmakiotis, I. Katsikis, and D. Panidis Association of polycystic ovary syndrome and fibromyalgia in a patient with primary hyperparathyroidism: a novel triad? - reply. Clin. Chem., June 1, 2006; 52(6): 1209 - 1210. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hahn, U. Haselhorst, B. Quadbeck, S. Tan, R. Kimmig, K. Mann, and O. E Janssen Decreased soluble leptin receptor levels in women with polycystic ovary syndrome Eur. J. Endocrinol., February 1, 2006; 154(2): 287 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Braillon, L. Mascitelli, F. Pezzetta, E. Mikhail, D. Cope, and D. A. Ehrmann Polycystic ovary syndrome. N. Engl. J. Med., June 30, 2005; 352(26): 2756 - 2757. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
